Prevalence of Viral Hepatitis B, C, and D in Kazakhstan.
Journal
TheScientificWorldJournal
ISSN: 1537-744X
Titre abrégé: ScientificWorldJournal
Pays: United States
ID NLM: 101131163
Informations de publication
Date de publication:
2022
2022
Historique:
received:
02
10
2021
revised:
14
03
2022
accepted:
31
03
2022
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
4
5
2022
Statut:
epublish
Résumé
Viral hepatitis is a major burden for the healthcare system worldwide. Up to date, a comprehensive analysis of the prevalence of viral hepatitis in Kazakhstan and Central Asia has not been carried out yet. Our epidemiological study aimed at investigating the frequency and spread of viral hepatitis B, C, and D depending on age and sex in Kazakhstan (5-year period). We utilized the data from the primary registration of the incidence of hepatitis B, C, and D in 18 regions of Kazakhstan (period: from 2015 to 2020). Age indicators, gender, and territorial characteristics of registered cases were determined and analysed. The data were obtained from the state information system "Electronic Register of Dispensary Patients", based on the International Classification of Diseases-10 for coding diseases. During the period studied, 268 975 cases of hepatitis B, C, and D were detected in Kazakhstan. Hepatitis B was registered in An analysis of the prevalence of hepatitis B, C, and D showed an increase in new cases in Kazakhstan. These findings indicate the need to develop effective preventive measures and screening strategies among people in a high-risk group. The results of the study can be used for the development of a national program to combat the spread of viral hepatitis.
Sections du résumé
Background
UNASSIGNED
Viral hepatitis is a major burden for the healthcare system worldwide. Up to date, a comprehensive analysis of the prevalence of viral hepatitis in Kazakhstan and Central Asia has not been carried out yet. Our epidemiological study aimed at investigating the frequency and spread of viral hepatitis B, C, and D depending on age and sex in Kazakhstan (5-year period).
Materials and Methods
UNASSIGNED
We utilized the data from the primary registration of the incidence of hepatitis B, C, and D in 18 regions of Kazakhstan (period: from 2015 to 2020). Age indicators, gender, and territorial characteristics of registered cases were determined and analysed. The data were obtained from the state information system "Electronic Register of Dispensary Patients", based on the International Classification of Diseases-10 for coding diseases.
Results
UNASSIGNED
During the period studied, 268 975 cases of hepatitis B, C, and D were detected in Kazakhstan. Hepatitis B was registered in
Conclusion
UNASSIGNED
An analysis of the prevalence of hepatitis B, C, and D showed an increase in new cases in Kazakhstan. These findings indicate the need to develop effective preventive measures and screening strategies among people in a high-risk group. The results of the study can be used for the development of a national program to combat the spread of viral hepatitis.
Identifiants
pubmed: 35492864
doi: 10.1155/2022/9102565
pmc: PMC9054462
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9102565Informations de copyright
Copyright © 2022 Almagul Jumabayeva et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Int J Drug Policy. 2007 Oct;18(5):426-32
pubmed: 17854732
Iran J Public Health. 2020 Jul;49(7):1269-1277
pubmed: 33083293
Infect Dis Clin North Am. 2019 Dec;33(4):1045-1062
pubmed: 31668190
J Zhejiang Univ Sci B. 2006 Sep;7(9):745-8
pubmed: 16909477
Viruses. 2020 Sep 30;12(10):
pubmed: 33008101
J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25050
pubmed: 29633520
Infect Disord Drug Targets. 2020;20(2):143-149
pubmed: 30663575
Sci Rep. 2019 Sep 26;9(1):13948
pubmed: 31558731
Am J Gastroenterol. 2020 Sep;115(9):1429-1438
pubmed: 32483003
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):135-184
pubmed: 30647010
Lancet Gastroenterol Hepatol. 2020 Sep;5(9):789
pubmed: 32730787
Epidemiol Infect. 2012 Jan;140(1):47-57
pubmed: 21324219
Lancet. 1997 Mar 22;349(9055):825-32
pubmed: 9121257
J Viral Hepat. 2017 Oct;24 Suppl 2:8-24
pubmed: 29105285
Transfus Clin Biol. 2017 Sep;24(3):189-195
pubmed: 28673499
J Hepatol. 2003;39 Suppl 1:S212-9
pubmed: 14708706
Epidemiol Infect. 2017 Oct;145(14):2873-2885
pubmed: 28891457
Liver Int. 2014 Aug;34(7):e308-16
pubmed: 24529078
Gastroenterol Clin North Am. 2020 Jun;49(2):179-189
pubmed: 32389357
Best Pract Res Clin Gastroenterol. 2017 Jun;31(3):347-355
pubmed: 28774417
Georgian Med News. 2016 Dec;(261):80-88
pubmed: 28132048
Sci Rep. 2019 Jul 11;9(1):10042
pubmed: 31296895
J Epidemiol Community Health. 2016 Jan;70(1):104-8
pubmed: 26254293
BMC Infect Dis. 2019 Dec 3;19(1):1027
pubmed: 31795979
Hepatol Med Policy. 2017 Jun 13;2:9
pubmed: 30288322
J Infect Dis. 2020 Apr 27;221(10):1677-1687
pubmed: 31778167
Indian J Med Ethics. 2020 Apr-Jun;V(2):103-105
pubmed: 32393447
BMC Public Health. 2019 Jan 10;19(1):47
pubmed: 30630464
Public Health Nurs. 2012 Jan-Feb;29(1):27-35
pubmed: 22211749
J Prev Med Hyg. 2016;57(2):E51-60
pubmed: 27582629
Int J Infect Dis. 2021 Mar;104:510-525
pubmed: 33385583
PLoS One. 2009 Dec 24;4(12):e8467
pubmed: 20041146
Eur J Clin Microbiol Infect Dis. 2008 Dec;27(12):1177-82
pubmed: 18551325
Gastroenterol Clin North Am. 2019 Jun;48(2):259-279
pubmed: 31046974
Lancet. 2016 Sep 10;388(10049):1081-1088
pubmed: 27394647
PLoS One. 2018 Nov 28;13(11):e0208036
pubmed: 30485377
Iran J Public Health. 2014 Feb;43(2):156-61
pubmed: 26060738
BMC Public Health. 2020 Sep 29;20(1):1461
pubmed: 32993585
Klin Lab Diagn. 2017 Mar;62(3):154-6
pubmed: 30620523
Int J Environ Res Public Health. 2018 Apr 02;15(4):
pubmed: 29614809
Harm Reduct J. 2019 Jan 5;16(1):1
pubmed: 30611251
Cent Asian J Glob Health. 2018 Feb 22;7(1):324
pubmed: 30863665
AIDS Rev. 2016 Apr-Jun;18(2):81-8
pubmed: 27196355
BMC Infect Dis. 2010 Jul 15;10:208
pubmed: 20630111
Sci Rep. 2019 Feb 14;9(1):2090
pubmed: 30765844
Vopr Virusol. 2015;60(1):34-6
pubmed: 26021072